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Background
Recent studies of antibodies in human plasma from
infected and immunized individuals revealed an impor-
tant role of the V1V2 region of the gp120 protein in
immune response. The function of V1V2-specific anti-
bodies and their potential in blocking the HIV-1 infec-
tion are still not well established. In this study we
present data about the appearance of such antibodies in
plasma from hundreds of patients from North America
and Africa, about their clade specificity, development
and neutralization activity.
Methods
Human plasma was isolated from infected individuals
and screened for anti V1V2 ELISA binding activity with
gp70/V1V2 fusion glycoproteins, representing clades B,
C and A/E sequences. All samples were tested in virus
neutralization assay for activity versus panel B, panel C,
and other Tier 2, pseudoviruses. Immunoaffinity chro-
matography of selected plasma, on gp70/V1V2 protein
columns, was used to isolate V1V2-specific antibodies.
Results
Most of the HIV-1 infected subjects (above 80%) have
robust levels of V1V2 binding activity versus the three
antigens. This activity was commonly detected in chronic
HIV-1 infection. Interestingly, the development of V1V2-
reactive antibodies tracked with the development of auto-
logous neutralizing antibodies. Immunoaffinity purified
V1V2-specific antibodies from selected broadly neutraliz-
ing plasma samples possessed broad neutralization activ-
ity with IC50’s generally in the 1 -20 μg/ml range.
Conclusion
Highly cross-reactive V1V2-specific Abs are present in
almost all broadly neutralizing human plasmas. These
antibodies are in large amounts and can be linear, con-
formational or quaternary epitope dependent. Such anti-
bodies are induced in humans (Thailand trial) and
because of that the region may be considered as immu-
nogenic. In addition, isolated anti-V1V2 antibodies show
neutralization activity toward Tier 2 viruses. The above
characteristics make the V1V2 region an important tar-
get for candidate HIV-1 vaccines.
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